Skip to main content

View full-text article in PMC

. 2018 Sep 3;13:2707–2720. doi: 10.2147/COPD.S167730

Table 3.

Exacerbation rates in the pooled REACT and RE²SPOND population (base case) and in the scenario analyses

Exacerbation severity	Exacerbation rate (95% CI)		Rate ratio (triple inhaled therapy + ROF vs triple inhaled therapy alone) (95% CI)	P-value
Exacerbation severity	Triple inhaled therapy + ROF	Triple inhaled therapy alone		P-value
Base case analysis
Moderate or severe	1.21 (1.11–1.33)^a	1.37 (1.26–1.49)^b	0.89 (0.78–1.00)	0.056
Moderate	0.77 (0.70–0.85)^a	0.84 (0.77–0.92)^b	0.92 (0.81–1.05)	0.220
Severe	0.32 (0.27–0.37)^a	0.37 (0.32–0.43)^b	0.86 (0.70–1.05)	0.137
Scenario analysis in patient population with prior hospitalization
Moderate or severe	1.28 (1.10–1.49)^c	1.72 (1.49–1.99)^d	0.74 (0.60–0.92)	0.005
Moderate	0.66 (0.56–0.79)^c	0.77 (0.65–0.91)^d	0.86 (0.68–1.09)	0.214
Severe	0.48 (0.39–0.60)^c	0.73 (0.60–0.89)^d	0.66 (0.49–0.88)	0.004

Notes:

^a

n=1,225;

^b

n=1,215;

^c

n=444;

^d

n=405.

Abbreviation: ROF, roflumilast.